These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 23290951)
41. Evolving role of platelet function testing in coronary artery interventions. Sharma RK; Voelker DJ; Sharma R; Reddy HK; Dod H; Marsh JD Vasc Health Risk Manag; 2012; 8():65-75. PubMed ID: 22371653 [TBL] [Abstract][Full Text] [Related]
42. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985 [TBL] [Abstract][Full Text] [Related]
43. Platelet function testing in patients with acute coronary syndrome. Orban M; Sibbing D J Cardiovasc Transl Res; 2013 Jun; 6(3):371-7. PubMed ID: 23397280 [TBL] [Abstract][Full Text] [Related]
44. High platelet reactivity and clinical outcome - fact and fiction. Sibbing D; Byrne RA; Bernlochner I; Kastrati A Thromb Haemost; 2011 Aug; 106(2):191-202. PubMed ID: 21505714 [TBL] [Abstract][Full Text] [Related]
45. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome. Ramaraj R; Movahed MR; Hashemzadeh M J Interv Cardiol; 2011 Jun; 24(3):199-207. PubMed ID: 21198849 [TBL] [Abstract][Full Text] [Related]
46. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678 [TBL] [Abstract][Full Text] [Related]
47. Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. Gurbel PA; Tantry US Thromb Haemost; 2011 Aug; 106(2):265-71. PubMed ID: 21713326 [TBL] [Abstract][Full Text] [Related]
48. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963 [TBL] [Abstract][Full Text] [Related]
49. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Capodanno D; Dharmashankar K; Angiolillo DJ Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):151-8. PubMed ID: 20136601 [TBL] [Abstract][Full Text] [Related]
50. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Toth PP Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Mariani M; Mariani G; De Servi S Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763 [TBL] [Abstract][Full Text] [Related]
52. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250 [TBL] [Abstract][Full Text] [Related]
57. Current oral antiplatelets: focus update on prasugrel. John J; Koshy SK J Am Board Fam Med; 2012; 25(3):343-9. PubMed ID: 22570398 [TBL] [Abstract][Full Text] [Related]
58. Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. Foo F; Oldroyd KG Biomark Med; 2011 Feb; 5(1):9-30. PubMed ID: 21319962 [TBL] [Abstract][Full Text] [Related]
59. Response to antiplatelet therapy is independent of endogenous thrombin generation potential. Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170 [TBL] [Abstract][Full Text] [Related]
60. Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome. Piccolo R; Di Gioia G; Niglio T; D'Anna C; De Rosa R; Strisciuglio T; Bevilacqua M; Piscione F; Cirillo P; Galasso G Angiology; 2014 Feb; 65(2):130-6. PubMed ID: 23221279 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]